BridgeBio Oncology Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview

Bridgebio Oncology Therapeutics

27/07/2026 21:16

BridgeBio Oncology Therapeutics Inc BBOT.OQ BBOT.O is expected to  report resultson July 29 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for BridgeBio Oncology Therapeutics Inc is for a loss of 57 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts had risen by about 0.6% in the last three months. ​
Wall Street's median 12-month price target for BridgeBio Oncology Therapeutics Inc is $23.00, about 160.8% above its last closing price of $8.82
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.53
-0.53
-0.53
Met
-0.6
Dec. 31 2026
-0.52
-0.52
-0.49
Beat
5.2
Sep. 30 2025
-0.46
-0.39
-1.03
Missed
-164.2​
​​
​
This summary was machine generated July 27 at 20:16 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)